Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intracavernosal Xeomin as Adjunctive Therapy to Tadalafil for Mild to Moderate Erectile Dysfunction
NCT07537855Phase 2Not yet recruiting
- Sponsor
- Northwestern University
- Start
- Sep 2026
- Primary completion
- Sep 2028
- Modality
- Recombinant Proteins and Enzymes
01
Overview
A Phase 2 trial of botulinum toxin type A in erectile dysfunction (ED), sponsored by Northwestern University. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
botulinum toxin type A
03
Conditions
erectile dysfunction (ED)
Beyond the preview
Go deeper on NCT07537855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07537855.